The healthcare system's treatment of chronic illness patients is a complex and deeply flawed issue that demands our attention. In this article, we'll delve into the challenges faced by individuals like my husband, who suffers from Crohn's disease, and explore the broader implications of an industry that prioritizes profit over patient well-being.
The Struggle for Adequate Coverage
Chronic illnesses, such as Crohn's disease, require specialized and often costly treatments. The introduction of innovative drugs like Humira (adalimumab) brought hope to many, but it also unveiled a dark side to our healthcare system. While Humira revolutionized treatment, its exorbitant price tag, reaching up to $7,000 per month, highlights a systemic issue.
The arrival of generic versions, or biosimilars, should have been a relief. However, the reality is far from ideal. These generics, while more affordable, still carry a hefty price, ranging from $1,500 to $3,500 per month. And here's the catch: insurance coverage falls short, leaving patients with significant out-of-pocket expenses.
Insurance: A Broken Promise
Insurance, designed to provide peace of mind, often fails to deliver when it matters most. For individuals with chronic illnesses, the promise of coverage turns into a financial burden. My husband and I, despite our relatively stable financial situation, face an annual healthcare cost of up to $25,000, which is nearly half of the median per capita income in Connecticut. This disparity is shocking and raises serious questions about the accessibility of healthcare.
The issue extends beyond financial strain. The bureaucratic maze of insurance companies leaves patients exhausted and frustrated. My husband, like many others, spends countless hours on the phone, fighting for the medication he needs. The system is broken, and it's not just about money; it's about the mental and emotional toll it takes on those already battling chronic illness.
A System Rigged Against Patients
The arrival of generic adalimumab has reduced costs for insurers but increased costs for patients. This paradoxical situation reveals the true nature of the healthcare industry: a profit-driven machine that values its bottom line over the well-being of its customers. The CEO of Molina Healthcare, the parent company of Connecticare, earned over $18 million in 2025, an amount that could provide life-saving medication to thousands. This stark contrast underscores the injustice inherent in our current system.
Approximately 74,000 Connecticut residents rely on high-cost biologics like adalimumab, and many face impossible choices between their medication and basic necessities like rent or food. This is not a sustainable or ethical situation.
A Call for Action
The solution, in my opinion, lies in a universal healthcare system funded by taxes on the ultra-wealthy. While this may seem like a distant dream, our lawmakers must take immediate action to protect their constituents. Insurance companies should be regulated to prevent them from exploiting their customers. These medications are not luxuries; they are lifelines.
We must pressure our representatives to prioritize the well-being of their constituents over corporate profits. The time for change is now, and we, as a society, have the power to demand a healthcare system that truly cares for its people.
